One-component nanomedicine

• Published in: Journal of controlled release Vol. 219; pp. 383 - 395
• Main Authors: Su, Hao, Koo, Jin Mo, Cui, Honggang
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 10.12.2015
• Subjects: Animals; Drug delivery; Drug Delivery Systems; Nanomedicine; Nanostructures - therapeutic use; Nanomedicine; Drug delivery
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2015.09.056

One-component nanomedicine (OCN) represents an emerging class of therapeutic nanostructures that contain only one type of chemical substance. This one-component feature allows for fine-tuning and optimization of the drug loading and physicochemical properties of nanomedicine in a precise manner through molecular engineering of the underlying building blocks. Using a precipitation procedure or effective molecular assembly strategies, molecularly crafted therapeutic agents (e.g. polymer-drug conjugates, small molecule prodrugs, or drug amphiphiles) could involuntarily aggregate, or self-assemble into nanoscale objects of well-defined sizes and shapes. Unlike traditional carrier-based nanomedicines that are inherently multicomponent systems, an OCN does not require the use of additional carriers and could itself possess desired physicochemical features for preferential accumulation at target sites. We review here recent progress in the molecular design, conjugation methods, and fabrication strategies of OCN, and analyze the opportunities that this emerging platform could open for the new and improved treatment of devastating diseases such as cancer. One-component nanomedicine (OCN) represents an emerging class of therapeutic nanostructures that contain only one type of chemical substance. [Display omitted]